SUMMARY Glucagon‐like peptide‐1 receptor (GLP‐1R) agonists have been shown to
regulate blood glucose concentrations by mechanisms including enhanced insulin …

Obective Glucagon‐like peptide‐1 (GLP‐1) receptor agonists are indicated for treatment of
type 2 diabetes since they mimic the actions of native GLP‐1 on pancreatic islet cells …

Purpose The increase in endothelin-1 (ET-1) and the decrease in endothelial nitric oxide
synthase (eNOS) both induce vasoconstriction and lead to molecular changes associated …

Recently, pleiotropic benefits of incretin therapy beyond glycemic control have been
reported. Although cancer is one of the main causes of death in diabetic patients, few reports …

Accumulating experimental and clinical evidences over the last decade indicate that GLP-1
analogues have a series of central nervous system and peripheral target tissues actions …

The complex pathological mechanisms responsible for development of type 2 diabetes are
not fully addressed by conventional drugs, which are also associated with inconvenient side …

Objective—TFEB (transcription factor EB) was recently reported to be induced by
atheroprotective laminar flow and play an anti-atherosclerotic role by inhibiting inflammation …

Exenatide once-weekly is an extended release formulation of exenatide, a glucagon-like
peptide–1 receptor agonist, which can improve glycemic control, body weight, blood …

OBJECTIVE The therapeutic potential of exendin-4, an agonist of the glucagon-like peptide-
1 receptor (GLP-1R), on diabetic polyneuropathy (DPN) in streptozotocin (STZ)-induced …

Glucagon-like peptide 1 (GLP-1), a kind of gut hormone, is used in the treatment of type 2
diabetes (T2D). Emerging evidence indicates that GLP-1 has anti-inflammatory activity …